目的:本文主要探讨HPV E6/E7 mRNA与薄层液基细胞学检测(Thinprep Cytologic Test, TCT)结合在子宫颈癌及癌前病变筛查中的价值。方法:选取2018年1月~2022年12月期间在延安市人民医院就诊的均进行过HPV E6/E7 mRNA、TCT的宫颈异常患者674例,以活检组织病理结果为金标准,分析不同检查方法对宫颈癌及癌前病变的筛查价值。结果:674例活检阳性的病例中:HPV E6/E7 mPNA检出阳性448例,TCT检出阳性371例;HPV E6/E7、TCT检查的诊断一致性为63.35%;与联合检测比较,HPV E6/E7 mRNA、TCT在宫颈癌前病变的检测中符合率均较低,差异均有统计学意义(P Objective: To analyze clinical application value of HPV E6/E7 mRNA and Thinprep cytologic test (TCT) detection in screening for cervical lesions. Methods: A total of 674 patients with cervical abnormalities who underwent HPV E6/E7 mRNA and TCT in Yan’an people’s Hospital from January 2018 to December 2022 were selected. With the histopathological results as the gold standard, the screening value of different examination methods for cervical cancer was analyzed. Results: Histopathological biopsies showed that the diagnostic concordance of HPV E6/E7 and TCT was 62.42%, and the sensitivity, specificity and accuracy of HPV E6/E7, TCT and colposcopy in detecting HSIL + SCC were all lower compared with the combined test, and the differences were statistically significant (P < 0.05). Conclusion The combination of HPV E6/E7 mPNA and TCT improve the value of screening for cervical cancer and may help in better clinical diagnosis and treatment.
目的:探讨人乳头状瘤病毒(HPV) E6/E7 mRNA与液基薄层细胞学检查(TCT)联合检测在宫颈癌风险预测中的应用价值。方法:选取2023年1月至2024年6月于延安市人民医院行宫颈癌和癌前病变筛查的216例患者作为研究对象,对其资料进行回顾性分析,该部分患者均同时行HPV E6/E7 mRNA与液基薄层细胞学检测联合及组织病理学检查,分析HPV E6/E7 mRNA与液基薄层细胞学单独检测及两者联合检测宫颈癌的灵敏性、特异性、阳性预测值及阴性预测值。结果:216例患者中,HPV E6/E7mRNA与液基薄层细胞学单独检测的敏感性、特异性、阳性预测值、阴性预测值分别为78.41%、42.50%、85.71%、30.91%和71.59%、62.50%、89.36%、33.33%;HPV E6/E7 mRNA与液基薄层细胞学联合检测的敏感性、特异性、阳性预测值、阴性预测值为93.19%、65.00%、92.13%、68.42%,差异均有统计学意义(P Purpose: To explore the application value of HPV E6/E7 mRNA and Thinprep cytologic test (TCT) in predicting the risk of cervical cancer. Methods: 216 patients who underwent HPV E6/E7 mRNA and TCT at Yan’an People’s Hospital from January 2023 to June 2024 were selected as the study subjects. The data were retrospectively analyzed. All patients underwent HPV E6/E7 mRNA combined with TCT and histopathological examination. The sensitivity, specificity, positive predictive value, and negative predictive value of HPV E6/E7 mRNA and TCT detected separately and combinedly for cervical cancer were analyzed. Results: Among 216 patients, the sensitivity, specificity, positive predictive value, and negative predictive value of HPV E6/E7 mRNA and TCT detected separately were 78.41%, 42.50%, 85.71%, 30.91% and 71.59%, 62.50%, 89.36% and 33.33%;The sensitivity, specificity, positive predictive value, and negative predictive value of combined detection of HPV E6/E7 mRNA and TCT were 93.19%,65.00%, 92.13%, and 68.42%, with statistically significant differences (P < 0.05). Conclusion: The combined det
